4.03
4.03 (0%)
As of Feb 14, 2025
Solid Biosciences Inc. [SLDB]
Source:
Company Overview
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, which we refer to collectively as our Candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, or Duchenne, SGT-212 for the treatment of Friedreich's ataxia, or FA, SGT-501 for the treatment of Catecholaminergic polymorphic ventricular tachycardia, or CPVT, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, or TNNT2 DCM, and additional assets for the treatment of genetic cardiac and other diseases, at different stages of development, with varying levels of investment.
| Country | United States |
| Headquarters | charlestown, massachusetts |
| Phone Number | 617-337-4680 |
| Industry | manufacturing |
| CEO | Alexander Cumbo |
| Website | solidbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-129.7 |
| Net Income | $-124.7 |
| Net Cash | $6.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -70.5% |
| Profit as % of Stockholder Equity | -90.9% |
Management Effectiveness
| Return on Equity | -90.9% |
| Return on Assets | -66.1% |
| Turnover Ratio | |
| EBITA | $-129.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $188.7 |
| Total Liabilities | $51.4 |
| Operating Cash Flow | $-100 |
| Investing Cash Flow | $-16.1 |
| Financing Cash Flow | $122.4 |
